Plasma 4Β-hydroxycholesterol: An endogenous CYP3A metric

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 2, 2009, Pages 147-153

  Tomalik Scharte, D ^a   Lutjohann D ^b   Doroshyenko, O ^a   Frank, D ^a   Jetter, A ^a,c   Fuhr, U ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4BETA HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; CYTOCHROME P450 3A; LOPINAVIR; MIDAZOLAM; RITONAVIR; UNCLASSIFIED DRUG; BENZILIC ACID DERIVATIVE; CHOLEST 5 ENE 3,4 DIOL; CHOLEST-5-ENE-3,4-DIOL; CHOLESTEROL; CYP3A PROTEIN, HUMAN; CYTOCHROME P450; ENZYME INHIBITOR; PROPIVERINE; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; ADULT; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; BENZILATES; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; HYDROXYCHOLESTEROLS; INFUSIONS, INTRAVENOUS; MALE; MIDAZOLAM; MIDDLE AGED; PHENOTYPE; PYRIMIDINONES; RITONAVIR;

EID: 67651183629     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.72     Document Type: Article

References (33)

1. Fuhr, U., Jetter, A. & Kirchheiner, J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin. Pharmacol. Ther. 81, 270-283 (2007).
2. Streetman, D.S., Bertino, J.S. Jr. & Nafziger, A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10, 187-216 (2000).
3. Galteau, M.M. & Shamsa, F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol. 59, 713-733 (2003).
4. Kovacs, S.J., Martin, D.E., Everitt, D.E., Patterson, S.D. & Jorkasky, D.K. Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin. Pharmacol. Ther. 63, 617-622 (1998).
5. Bodin, K. et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J. Biol. Chem. 276, 38685-38689 (2001).
6. Josephson, F. et al. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur. J. Clin. Pharmacol. 64, 775-781 (2008).
7. Marschall, H.U. et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129, 476-485 (2005).
8. Niemi, M. et al. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet. Genomics 16, 565-568 (2006).
9. Diczfalusy, U. et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics 18, 201-208 (2008).
10. Wang, Y.H., Jones, D.R. & Hall, S.D. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab. Dispos. 33, 664-671 (2005).
11. Mirghani, R.A., Ericsson, O., Tybring, G., Gustafsson, L.L. & Bertilsson, L. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur. J. Clin. Pharmacol. 59, 23-28 (2003).
12. Bodin, K. et al. Metabolism of 4 beta-hydroxycholesterol in humans. J. Biol. Chem. 277, 31534-31540 (2002).
13. Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., Hamman, M.A., O'Mara, E.M. Jr. & Hall, S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64, 133-143 (1998).
14. Tomalik-Scharte, D. et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab. Dispos. 33, 1859-1866 (2005).
15. Kinirons, M.T. et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin. Pharmacol. Ther. 66, 224-231 (1999).
16. Masica, A.L., Mayo, G. & Wilkinson, G.R. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin. Pharmacol. Ther. 76, 341-349 (2004).
17. Benet, L.Z. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol. Interv. 5, 79-83 (2005).
18. Kharasch, E.D., Thummel, K.E. & Watkins, P.B. CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol. Interv. 5, 151-153 (2005).
19. Jochemsen, R., van Rijn, P.A., Hazelzet, T.G., van Boxtel, C.J. & Breimer, D.D. Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. Biopharm. Drug Dispos. 7, 53-61 (1986).
20. Diczfalusy, U., Kanebratt, K.P., Bredberg, E., Andersson, T.B., Böttiger, Y. & Bertilsson, L. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br. J. Clin. Pharmacol. 67, 38-43 (2009).
21. Klotz, U. & Ziegler, G. Physiologic and temporal variation in hepatic elimination of midazolam. Clin. Pharmacol. Ther. 32, 107-112 (1982).
22. Klotz, U. & Reimann, I.W. Chronopharmacokinetic study with prolonged infusion of midazolam. Clin. Pharmacokinet. 9, 469-474 (1984).
23. Kharasch, E.D., Bedynek, P.S., Park, S., Whittington, D., Walker, A. & Hoffer, C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin. Pharmacol. Ther. 84, 497-505 (2008).
24. Kharasch, E.D., Bedynek, P.S., Walker, A., Whittington, D. & Hoffer, C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin. Pharmacol. Ther. 84, 506-512 (2008).
25. Walter, R., Ullmann, C., Thummler, D. & Siegmund, W. Influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats. Drug Metab. Dispos. 31, 714-717 (2003).
26. Wide, K., Larsson, H., Bertilsson, L. & Diczfalusy, U. Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br. J. Clin. Pharmacol. 65, 708-715 (2008).
27. Emoto, C. & Iwasaki, K. Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 36, 219-233 (2006).
28. Tomalik-Scharte, D. et al. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur. J. Clin. Pharmacol. 64, 1033-1035 (2008).
29. Wyen, C. et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin. Pharmacol. Ther. 84, 75-82 (2008).
30. Klaassen, T. et al. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. Eur. J. Clin. Pharmacol. 64, 387-398 (2008).
31. Lütjohann, D. et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69, 431-438 (2004).
32. Breuer, O. Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma. J. Lipid Res. 36, 2275-2281 (1995).
33. Steinijans, V.W., Hartmann, M., Huber, R. & Radtke, H.W. Lack of pharmacokinetic interaction as an equivalence problem. Int. J. Clin. Pharmacol. Ther. Toxicol. 29, 323-328 (1991).